| Date | Title | | | 12/10/12 | Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and Other Bleeding Disorders at 54th American Society of Hematology (ASH) Annual Meeting|
– Efficacy for ALN-AT3, an RNAi Therapeutic Targeting Antithrombin
for the Treatment of Hemophilia, Demonstrated in Non-Human Primate
Models –
– Progress from the Therapeutic Program to be Included in an Upcoming
RNAi Roundtable on Conjugate Delivery –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 10, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has presented... |
|  | | 12/08/12 | Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemoglobinopathies at 54th American Society of Hematology (ASH) Annual Meeting|
– ALN-TMP, an RNAi Therapeutic Targeting Tmprss6 for the Treatment of
Hemoglobinopathies, Shows Disease Modifying Effects in Model of
β-Thalassemia including Correction of Globin Gene Expression –
– Results Also Published in the Journal “Blood” –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has presented new pre-clini... |
| | | 11/27/12 | Alnylam to Webcast Presentation at Deutsche Bank 2012 dbAccess BioFEST| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 27, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Deutsche Bank 2012 dbAccess BioFEST on
Monday, December 3, 2012 at 7:50 a.m. ET at the Four Seasons Hotel in
Boston.
A live audio webcast of the presentation will be available on the News &
Investors section of the company’... |
| | | 11/26/12 | Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patents from the Tuschl II Patent Estate Broadly Covering RNAi Therapeutics| – New Composition of Matter and Method of Use Claims Allowed in Three Patent Applications –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate. The USPTO has allowed claims in patent applications 12/537,602 , 12/683,08... |
| | | 11/21/12 | Alnylam to Webcast Presentation at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 24th Annual Piper Jaffray Healthcare Conference on
Wednesday, November 28, 2012 at 11:00 a.m. ET at the New York Palace in
New York City.
In addition, Alnylam management will present a company overview at the 11th
Annual J.P. M... |
| | | 11/14/12 | Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency|
– New Research Presented at 63rd Annual
Meeting of the American Association for the Study of Liver Diseases
(AASLD, “The Liver Meeting”) –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY) ,
a leading RNAi therapeutics company, announced today that it has
presented new
pre-clinical data with an RNAi therapeutic targeting alpha-1
antitrypsin (AAT) for the treatment of liver dis... |
| | | 11/12/12 | Alnylam and Tekmira Restructure Relationship and Settle All Litigation| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 12, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY)
announced today that they and Tekmira Pharmaceuticals Corporation have
restructured their relationship with a new licensing agreement and have
resolved all litigation between the parties in a settlement agreement.
The new license agreement consolidates and clarifies certain
intellectual property (IP) elements related to lipid nanoparticle (LNP)
... |
| | | 11/12/12 | Alnylam to Webcast Conference Call to Discuss Restructuring of Relationship with Tekmira|
Conference Call on Tuesday, November 13, 2012 at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 12, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced that management will host a
conference call on Tuesday, November 13, 2012 at 8:00 a.m. ET to discuss
the restructuring of its relationship with Tekmira including a new
licensing agreement and a resolution of all litigation between t... |
| | | 11/08/12 | Regulus to Present at the Lazard Capital Markets Healthcare Conference|
LA JOLLA, Calif., Nov. 8, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012 at 1:00 PM EST at the Pierre Hotel in New York City.
The presentation will be w... |
| | | 11/07/12 | Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors| Stanley T. Crooke, M.D., Ph.D. and Barry E. Greene to Step Down
LA JOLLA, Calif., Nov. 7, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Douglas E. Williams, Ph.D. to its Board of Directors. Concurrently, Stanley T. Crooke, M.D., Ph.D., Chairman of the Board and CEO of Isis Pharmaceuticals, Inc., and Barry E. Greene, President and Ch... |
| | | 11/05/12 | Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions|
LA JOLLA, Calif., Nov. 5, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, summarized today its recent financing activity that the company expects will enable Regulus to execute its current strategic objectives for the foreseeable future.
In connection with Regulus' Initial Public Offering (IPO), which closed on October 10, 2012, and other recent financial transaction... |
| | | 11/05/12 | Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial Results|
– Continued to Execute on ‘Alnylam 5x15’ Product Strategy with
Positive Clinical Data from ALN-TTR02 for the Treatment of Transthyretin
(TTR)-Mediated Amyloidosis (ATTR) –
– Formed Multiple Strategic Collaborations Resulting in Over $50
Million in Upfront Payments including Genzyme for ALN-TTR in Japan and
other Asian-Pacific Countries, and Monsanto for RNAi Applications in
Agriculture –
– Maintained Strong Balance Sheet wi... |
| | | 11/03/12 | Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012| -Regulus, in partnership with Sanofi, is developing novel anti-fibrotic therapies targeting microRNAs-
LA JOLLA, Calif., Nov. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data targeting microRNA-21 (miR-21) will be presented at 10:00 a.m. PDT on November 3, 2012 in a late-breaking poster session at the Ameri... |
| | | 11/01/12 | Alnylam to Webcast Conference Call Discussing Third Quarter 2012 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the third quarter ending September 30, 2012 on Monday,
November 5, 2012, after the U.S. financial markets close.
Management will provide an update on the company, discuss third quarter
results, and discuss expectations for the future via conference call o... |
| | | 10/22/12 | Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia| – Genzyme to Advance ALN-TTR02 and ALN-TTRsc Programs as Breakthrough Therapies for Patients with ATTR in Japan and in the Broader Asian Market –
– Alnylam to Receive $22.5 Million in Upfront Payment in Addition to Milestone Payments and Royalties on Product Sales; Alnylam Maintains All Rights in U.S., Europe, and Rest of World –
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY)... |
| | | 10/22/12 | Alnylam to Host Conference Call to Discuss Alliance with Genzyme to Develop and Commercialize RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis in Asia|
– Conference Call to be held Today, October 22 at 8:00 a.m. ET –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2012--
Alnylam
Pharmaceuticals (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
host a conference call today at 8:00 a.m. ET to discuss its newly formed
alliance with Genzyme, a Sanofi company, to develop and commercialize
RNAi therapeutics targeting transthyretin (TTR) for the treatment ... |
| | | 10/09/12 | Alnylam Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 9, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that the Japanese Patent Office upheld key
claims in the Tuschl II patent (JP4095895) in an invalidation trial held
in Japan. The invalidation request was made by Bio Think-Tank, a
Japanese company.
“We are extremely pleased with the outcome of the invalidation trial
which resulted ... |
| | | 10/04/12 | Regulus Announces Pricing of Initial Public Offering|
LA JOLLA, Calif., Oct. 4, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of its initial public offering of 11,250,000 shares of its common stock at $4.00 per share. Regulus has also granted the underwriters a 30-day option to purchase up to an additional 1,687,500 shares at the initial public offering price to cover overallotments, if any. ... |
| | | 09/25/12 | Alnylam Wins Rulings in Patent Infringement Case against Tekmira|
- Alnylam Expands Infringement Action with Suit in Canada -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 25, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that the U.S. District Court of the District of
Massachusetts has ruled in favor of Alnylam and has denied Tekmira
Pharmaceuticals Corporation’s motion to dismiss
certain claims and motion to disqualify
Alnylam’s counsel i... |
| | | 09/13/12 | Alnylam to Webcast Presentation at UBS Global Life Sciences Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the UBS Global Life Sciences Conference on Thursday, September 20,
2012 at 11:00 a.m. ET at the Grand Hyatt in New York City.
A live audio webcast of the presentation will be available on the News &
Investors section of the company’s ... |
| | | 09/04/12 | Alnylam Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection|
– ALN-RSV01 Reduces Bronchiolitis Obliterans Syndrome (BOS) in
RSV-Infected Lung Transplant Patients –
– Alnylam to Discuss Results with U.S. and European Regulatory
Authorities and Communicate Future Development Plans at Year End –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today complete results from its Phase IIb trial... |
| | | 09/04/12 | Alnylam to Webcast Presentation at Upcoming Investor Conferences|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 10:50 a.m. ET at the Waldorf=Astoria hotel in New York City.
In addition, Alnylam management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012 at 1:30 p.m... |
| | | 08/29/12 | Alnylam to Webcast Presentation at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the Rodman & Renshaw Annual Global Investment Conference on Monday,
September 10, 2012 at 10:50 a.m. ET at the Waldorf=Astoria hotel in New
York City.
In addition, Alnylam management will present a company overview at the
Morgan... |
| | | 08/28/12 | Alnylam and Monsanto Form Strategic Alliance| CAMBRIDGE, Mass. & ST. LOUIS--(BUSINESS WIRE)--Aug. 28, 2012--
Monsanto
Company (NYSE: MON) and Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today they
have formed a strategic alliance to advance biological technologies in
the field of agriculture. The new alliance brings Alnylam’s broad
RNAi-based intellectual property (IP) and proprietary technologies to
Monsanto’s new BioDirect™ technology, which aims to deliver innovative
... |
| | | 08/22/12 | Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer|
– RNAi Silencing of PD-1 Ligands Significantly Boosts Dendritic Cell
Immunogenicity Toward Tumor Antigens –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 22, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and collaborators at Radboud University Nijmegen Medical Centre
in the Netherlands announced today that they have published new
pre-clinical results in the journal Cancer Immunology Immunotherapy
... |
| | | 08/20/12 | Regulus Files Registration Statement for Proposed Initial Public Offering|
LA JOLLA, Calif., Aug. 20, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Regulus. The number o... |
| | | 08/15/12 | Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy| - Initial focus on discovery of microRNAs as biomarkers for multiple sclerosis (MS) -
LA JOLLA, Calif., Aug. 15, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a collaboration with Biogen Idec (NASDAQ: BIIB) to identify microRNAs as biomarkers for multiple sclerosis (MS). Under the transaction, Biogen Idec will make an investment in Regulus i... |
| | | 08/14/12 | Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca|
Focused on three exclusive microRNA targets
LA JOLLA, Calif., Aug. 14, 2012 – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic... |
| | | 08/06/12 | Alnylam Presents New Data from its Conjugate Delivery Platform, Enabling Subcutaneous Administration of RNAi Therapeutics with Wide Therapeutic Index|
– New Pre-clinical Data from ‘Alnylam5x15’ Programs Including
ALN-TTRsc for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
and ALN-AT3 for the Treatment of Hemophilia –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2012--
Alnylam
Pharmaceuticals, Inc.(Nasdaq: ALNY), a
leading RNAi therapeutics company, is presenting new data
today from its GalNAc-conjugate siRNA programs for the systemic delivery
of RNAi therapeutics at... |
| | | 08/06/12 | Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial Results|
– Reported Positive Clinical Data from Three RNAi Therapeutic
Programs in Quarter and Recent Period: ALN-TTR02 for the Treatment of
Transthyretin-Mediated Amyloidosis; ALN-PCS for the Treatment of Severe
Hypercholesterolemia; and, ALN-RSV01 for the Treatment of Respiratory
Syncytial Virus Infection –
– Maintained Strong Balance Sheet with $293 Million in Cash –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2012--
Alnylam
Ph... |
| | | 07/31/12 | Alnylam to Webcast Conference Call Discussing Second Quarter 2012 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 31, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the second quarter ending June 30, 2012 on Monday, August 6,
2012, after the U.S. financial markets close.
Management will provide an update on the company, discuss second quarter
results, and discuss expectations for the future via conference call on
... |
| | | 07/30/12 | Alnylam Earns Milestone Payment from GlaxoSmithKline in VaxiRNA Collaboration on Flu Vaccine Production| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 30, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has earned a
development milestone payment from GlaxoSmithKline (GSK), totaling $3.2
million. The milestone payment is related to progress in the companies’
collaboration on the use of VaxiRNA™ technology for the production of
GSK influenza vaccine. Alnylam’s VaxiRNA platform uses RNAi te... |
| | | 07/16/12 | Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of Serum Transthyretin (TTR) of up to 94% After Single Dose|
– Results of Clinical Study Demonstrate Rapid, Dose-Dependent,
Durable, and Specific Knockdown of TTR, the Disease-Causing Protein in
TTR-Mediated Amyloidosis (ATTR) –
– Company to Host Conference Call Today, July 16 at 8:30 a.m. ET to
Discuss Results –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today the achievement of
... |
| | | 07/13/12 | Alnylam and Collaborators Publish Scientific Paper Documenting Discovery of Second Generation MC3 Lipid Nanoparticles (LNPs)|
– Seminal Paper by Scientists from Alnylam, AlCana, and the
University of British Columbia Shows Rational Design, Synthesis, and
Evaluation of More Than 50 Novel Lipids and Delineation of Critical
Parameters for Potent In Vivo Efficacy –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 13, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, and collaborators announced today the
publication of a scien... |
| | | 07/12/12 | Alnylam and Ascletis Form Strategic Collaboration to Develop ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers|
Partnership is Focused on Developing ALN-VSP for Hepatocellular
Carcinoma (HCC) in China, with Alnylam Retaining Rest-of-World Rights
CAMBRIDGE, Mass. & HANGZHOU, China & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul. 12, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and Ascletis
Pharmaceuticals (Hangzhou) Co., Ltd.., a privately held US-China
joint venture pharmaceutical company... |
| | | 07/11/12 | Alnylam Presents New Pre-clinical Data with its RNAi Therapeutic Program in Hemophilia|
– Advances an RNAi Therapeutic Targeting Antithrombin for the
Treatment of Hemophilia in its ‘Alnylam 5x15’ Product Strategy –
– Designates ALN-AT3, a Potent GalNAc-siRNA Conjugate Enabling
Subcutaneous Administration, as Development Candidate –
– Demonstrates Pre-Clinical Proof of Concept in Animal Models of
Hemophilia –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 11, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: AL... |
| | | 07/03/12 | Alnylam to Webcast Presentation at the Seventh Annual JMP Securities Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 3, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Seventh Annual JMP Securities
Healthcare Conference on Thursday, July 12, 2012 at 11:00 a.m. ET at the
Peninsula New York.
A live audio webcast of the presentation will be available on the News &
Investors section of the com... |
| | | 06/27/12 | Alnylam Expands and Develops Management Team|
– Appoints Oved Amitay to Vice President, Head of Commercial –
– Promotes Akshay Vaishnaw to Executive Vice President and Chief
Medical Officer;
Jared Gollob to Vice President, Clinical
Research; and,
Lubomir Nechev to Vice President, Process
Sciences –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it ha... |
| | | 06/19/12 | Alnylam Receives Orphan Drug Designation from U.S. Food & Drug Administration for ALN-TTR02, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 19, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that the U.S. Food &
Drug Administration (FDA) has provided Orphan Drug Designation to
ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic
polyneuropathy (FAP), one of the predominant clinical manifestations of
transthyretin (TTR)-mediated amyloidosis (ATTR).
“... |
| | | 06/12/12 | Alnylam and Collaborators Publish New Pre-clinical Results with an RNAi Therapeutic Approach for Inducing Endogenous Erythropoiesis for the Treatment of Anemia|
– New Paper Published in Blood Shows
Potent and Selective Induction of Liver Erythropoietin through Silencing
of EglN Genes –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced the publication of new pre-clinical results in the
journal Blood
(doi: 10.1182/blood-2012-04-423715) that describe targeting the
egg-laying nine homolog (E... |
| | | 06/07/12 | Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)|
– Company to Present Data from Phase I Study Early in Third Quarter –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has completed
enrollment in its Phase I trial with ALN-TTR02, an RNAi therapeutic
targeting the transthyretin (TTR) gene for the treatment of TTR-mediated
amyloidosis (ATTR). Alnylam also announced today that it ... |
| | | 06/04/12 | Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting|
– Complete Response Achieved in Endometrial Cancer Patient with
Multiple Liver Metastases –
– Results Provide Additional Safety Data on Longer Term Dosing with
RNAi Therapeutics Delivered with Lipid Nanoparticles (LNPs) –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced results today from its Phase I extension study with
ALN-VSP... |
| | | 05/30/12 | Alnylam Announces Top-Line Results of Phase IIb Clinical Trial of ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection| – Study in RSV-Infected Lung Transplant Patients Narrowly Misses Primary “Intent-to-Treat” Endpoint, but Meets Pre-Specified “Last Observation Carried Forward” and “Per Protocol” Endpoints with Clinically Meaningful Treatment Effect of over 50% for Reduction of Bronchiolitis Obliterans Syndrome –
– Alnylam to Discuss Results with U.S. and EU Regulatory Authorities and Provide Further Guidance in the Second Half of 2012 –
– Alnylam to Host Conference Call at 8:45 a.m. ET Today to Discuss Resu... |
| | | 05/23/12 | Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent| CAMBRIDGE, Mass. & NORWICH, United Kingdom--(BUSINESS WIRE)--May. 23, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and Plant
Bioscience Limited (PBL), a technology development and intellectual
property (IP) management company, announced today that they have entered
into a licensing agreement. PBL has granted Alnylam a world-wide,
non-exclusive license to the Baulcombe patent (U.S. Patent No.
... |
| | | 05/10/12 | Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)|
– Results Demonstrate Rapid, Dose-Dependent, and Durable Lowering of
Both Wild-Type and Mutant TTR Protein Levels, and Show Human Proof of
Concept for RNAi Therapeutics using First-Generation Lipid Nanoparticle
(LNP) Delivery –
– Alnylam On Track for Presenting Phase I Clinical Trial Data for
ALN-TTR02, using Second-Generation LNP Delivery, in the Third Quarter of
2012 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 10, 2012--
... |
| | | 05/09/12 | Alnylam to Webcast Presentation at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 9, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 11th Annual JMP Securities Research Conference on Tuesday, May 15
at 2:30 p.m. PT at the Ritz-Carlton in San Francisco.
In addition, Alnylam management will present a company overview at the
Bank of America Merrill Lynch Health Care Co... |
| | | 05/03/12 | Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results| - Continued Progress with "Alnylam 5x15" including Initiation of Phase I Trial with ALN-TTR02 -
- Reported Positive Clinical Results for ALN-PCS with up to 84% Knockdown of PCSK9 and 50% Lowering of LDL Cholesterol in Single Dose, Statin-Free Phase I Trial -
- Reports Approximately $317 Million in Cash and Expects to End 2012 with Greater than $250 Million in Cash -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 3, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics c... |
| | | 04/30/12 | Regulus Therapeutics Appoints Bruce Carter to its Board of Directors|
LA JOLLA, Calif., April 30, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Bruce Carter, Ph.D. to its Board of Directors. Dr. Carter currently serves as an independent member of the Board of Directors of Immune Design Corp., a privately held biotech company located in Seattle, and as a board member of additional scientific organizations. He previo... |
| | | 04/26/12 | Alnylam to Webcast Conference Call Discussing First Quarter 2012
Financial Results| CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) --Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the first quarter ending March 31, 2012 on Thursday, May 3,
2012, after the U.S. financial markets close.
Management will provide an update on the company, discuss first quarter
results, and discuss expectations for the future via conference call on
May 3, 2012 at 4:... |
| | | 04/23/12 | Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and
Scientific Advisory Board| - Appointment of Academic Leader and Esteemed Physician Scientist
Augments Clinical Expertise on Boards -
CAMBRIDGE, Mass., Apr 23, 2012 (BUSINESS WIRE) --Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, announced today the election of Dennis A.
Ausiello, M.D. to its Board of Directors and Scientific Advisory Board.
Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard
Medical School and Chief of... |
| | | 04/20/12 | Alnylam Reports Positive Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia| - PCSK9 Synthesis Inhibitor Achieves up to 84% Knockdown of PCSK9 and
50% Lowering of LDL Cholesterol in Single Dose, Statin-Free Phase I
Trial -
- New Results Highlight Continued Improved Efficacy and Safety for
Alnylam Second-Generation Lipid Nanoparticles (LNP) -
CAMBRIDGE, Mass., Apr 20, 2012 (BUSINESS WIRE) --Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today positive resu... |
| | | 04/13/12 | Alnylam to Webcast Presentation at Future Leaders in the Biotech
Industry Conference| CAMBRIDGE, Mass., Apr 13, 2012 (BUSINESS WIRE) --Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Future Leaders in the Biotech Industry
Conference on Friday, April 20, 2012 at 10:00 a.m. ET at the Millennium
Broadway Hotel in New York City.
A live audio webcast of the presentation will be available on the News &
Investors section of the ... |
| | | 03/27/12 | Alnylam to Webcast Presentation at 11th Annual Needham Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 27, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 11th Annual Needham Healthcare Conference on Wednesday, April 4,
2012 at 10:40 a.m. ET at the New York Palace Hotel.
A live audio webcast of the presentation will be available on the News &
Investors section of the company’s websi... |
| | | 03/19/12 | Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)|
– Data Demonstrating TTR Knockdown Expected in Third Quarter of 2012 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has initiated
dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic
targeting the transthyretin (TTR) gene for the treatment of TTR-mediated
amyloidosis (ATTR). The study is aimed at evaluati... |
| | | 03/14/12 | Alnylam Retains Key Claims for Kinesin Spindle Protein (KSP) RNAi Patent in Interference Proceedings| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that the United
States Patent and Trademark Office (USPTO) has maintained key claims in
the company’s KSP RNAi patent (US Patent No. 7,718,629) in interference
proceedings. The interference was declared on February 28, 2011, between
Alnylam’s patent and a patent application (US Patent Application... |
| | | 03/06/12 | Alnylam to Webcast Presentation at Barclays Capital Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the Barclays Capital Global Healthcare Conference on Tuesday, March
13, 2012 at 4:15 p.m. ET at the Loews Miami Hotel, Florida.
A live audio webcast of the presentation will be available on the News &
Investors section of the company’s... |
| | | 03/01/12 | Alnylam and the University of Massachusetts Medical School Announce Tuschl I Patent Upheld in European Opposition Proceedings| CAMBRIDGE, Mass. & WORCESTER, Mass.--(BUSINESS WIRE)--Mar. 1, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and the University of Massachusetts Medical School (UMMS)
reported today that the European Patent Office (EPO) has upheld the
Tuschl I ’726 patent (EP 1309726) in oral opposition proceedings held in
Munich, Germany. The requested claims of the ’726 patent were upheld
without any modificatio... |
| | | 02/29/12 | Alnylam to Webcast Presentation at Cowen and Company 32nd Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Cowen and Company 32nd
Annual Health Care Conference on Wednesday, March 7, 2012 at 9:20 a.m.
ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the News &
Investors sectio... |
| | | 02/16/12 | Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis| -New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney
-Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs
LA JOLLA, Calif., Feb. 16, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-2... |
| | | 02/15/12 | Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 15, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that the underwriters of its
previously announced public offering of common stock have exercised
their option to purchase an additional 1,125,000 shares at a public
offering price of $10.75 per share. As a result, the company will issue
a total of 8,625,000 shares in the offering and will receive aggreg... |
| | | 02/14/12 | Alnylam Pharmaceuticals Prices Public Offering of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced the pricing of an underwritten
registered public offering of 7,500,000 shares of its common stock at a
public offering price of $10.75 per share. All of the shares are being
sold by Alnylam. The offering is expected to close on February 21, 2012,
subject to customary closing conditions.
J... |
| | | 02/13/12 | Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it has commenced an
underwritten public offering of 7,000,000 shares of its common stock.
All of these shares are being sold by Alnylam.
J.P. Morgan Securities LLC is acting as sole book-running manager for
the proposed offering. Alnylam intends to grant the underwriter a 30-day
opti... |
| | | 02/10/12 | Alnylam to Webcast Presentations at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that management will present a
company overview at the 14th Annual BIO CEO & Investor
Conference on Tuesday, February 14, 2012 at 3:30 p.m. ET and at the
Leerink Swann 2012 Global Healthcare Conference on Wednesday, February
15, 2012 at 3:30 p.m. ET, both being held at the Waldorf=Astoria in New
... |
| | | 02/09/12 | Alnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples|
– Circulating Extracellular RNA Detection (cERD) Method Enables
Quantitative Measurement of Tissue-Specific mRNA Silencing –
– Company to Enable Academic Research and to Provide Broad Licenses
to Industry –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that its scientists have discovered a novel
method for monitoring RN... |
| | | 02/09/12 | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results|
– Achieved Positive Clinical Data in Multiple RNAi Therapeutics
Programs Including RNAi Proof of Mechanism with ALN-VSP for Liver
Cancers, Human Proof of Concept with ALN-TTR for Transthyretin-Mediated
Amyloidosis, and Clinical Efficacy with ALN-PCS for Severe
Hypercholesterolemia –
– Progressed Additional ‘Alnylam 5x15’ RNAi Therapeutics Programs in
Hemophilia, Refractory Anemia, and Hemoglobinopathies –
– Maintained Stron... |
| | | 02/02/12 | Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the fourth quarter and year ending December 31, 2011 on
Thursday, February 9, 2012, after the U.S. financial markets close.
Management will provide an update on the company, discuss fourth quarter
and year-end 2011 results, and discuss expectations for th... |
| | | 01/30/12 | Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi Therapeutics|
– New Patent Allowance Covers Seminal Invention of “MC3” Lipid –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that the United
States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for patent application number 12/813,448, covering the
company’s proprietary second generation lipid nanoparticle (LNP)
platf... |
| | | 01/19/12 | Alnylam to Restructure Organization, Aligning Resources with Focus on Highest Value Pipeline Opportunities in “Alnylam 5x15™” Product Strategy| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 19, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it intends to implement a strategic
corporate restructuring, including an approximate 33% reduction in its
workforce, as it aligns its resources to focus on what it believes to be
the company’s highest value opportunities with accelerated clinical
development plans. These include a previousl... |
| | | 01/17/12 | Alnylam Files Patent Infringement Suit Against Tekmira| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Pharmaceuticals Corporation in the U.S. District Court of the District of Massachusetts. Alnylam’s infringement suit against Tekmira is based upon Tekmira’s research activities providing lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) molecules to a pharmaceutical col... |
| | | 01/08/12 | Alnylam Provides Key 2012 Goals for RNAi Therapeutics Pipeline| – Focuses Near-Term ‘Alnylam 5x15’ Efforts on Highest Value Opportunities in Transthyretin-Mediated Amyloidosis and Hemophilia with Accelerated Clinical Development –
– Aims to Advance Additional Pipeline Programs with Existing Alliances and New Partnerships –
– Increases Guidance to End 2011 with Approximately $260M in Cash –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2012-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key “Al... |
| | | 01/06/12 | Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis|
– Company Expects to Initiate Trial in First Half of 2012 with Data
in Third Quarter of 2012 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has filed a Clinical Trial Application
(CTA) with the U.K. Medicines and Healthcare products Regulatory Agency
(MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi
t... |
| | | 01/05/12 | Regulus Therapeutics to Present microRNA Platform and Pipeline Updates at Two Leading Scientific Conferences| -New Pre-clinical Data to be Presented on Proprietary Therapeutic Programs in Metabolic Disease and Cancer at Keystone Symposium and AACR Special Conference
LA JOLLA, Calif., Jan. 5, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data from its proprietary lead program targeting microRNA-33a/b (miR-33a/b), currently in preclinical development for ... |
| | | 01/05/12 | Alnylam and Arrowhead Form Collaboration and Licensing Agreement|
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic
Toward Hepatitis B Virus (HBV) –
– Alnylam Gains Access to Arrowhead’s Dynamic Polyconjugate (DPC)
Delivery Technology for “Alnylam 5x15” Target –
CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, and Arrowhead
Research Corporation, (Nasdaq: ARWR) a na... |
| | | 01/04/12 | Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia|
– RNAi Therapeutic Achieves Robust Silencing of PCKS9 and Reductions
of Over 50% in LDL Cholesterol, a Validated Clinical Endpoint –
– Results Highlight Major Potency Improvements of Second-Generation
Lipid Nanoparticle Platform in Man –
– Alnylam to Host Conference Call Today, January 4 @ 8:30 a.m. ET to
Discuss Results –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: AL... |
| | | 01/04/12 | Alnylam to Webcast Presentation at 30th Annual J.P. Morgan Healthcare Conference 2012| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that management will present a
company overview at the 30th Annual J.P. Morgan Healthcare
Conference 2012 on Wednesday, January 11, 2012 at 7:30 a.m. PT (10:30
a.m. ET) at the Westin St. Francis in San Francisco, Calif. This
presentation will include a review of the company's 2011 goals and its
go... |
| |
|
